GSK’s Menveo meningococcal vaccine in new single-vial, fully …
WEB1 day ago — GSK plc (LSE/NYSE: GSK) today announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended for use a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease ...
GSK: CHMP Issues Positive Opinion On New Fully Liquid …
WEB1 day ago — (RTTNews) - GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended for use a single-vial, fully liquid presentation of ...
GSK celebrates positive EU opinion of liquid Menveo vaccine
WEB1 day ago — September 24, 2024 at 04:18 am EDT. (Alliance News) - GSK PLC on Tuesday announced a new positive opinion from the EU's European Medicine Agency's Committee for Medicinal Products for Human Use. The London-based pharmaceutical company said the committee recommended its new single-vial, fully liquid presentation of its invasive meningococcal ...
Positive EU opinion for GSK liquid Menveo vaccine
WEB1 day ago — GSK's. Menveo. meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion. · If approved, the fully liquid presentation will offer healthcare providers an option that does not require reconstitution of Menveo (MenACWY vaccine) before use. · Marketing authorisation in EU expected by November 2024.
US FDA approves Menveo in a new single-vial presentation to help ... - GSK
WEBOct 17, 2022 — GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a new presentation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease …
GSK announces first participant vaccinated in phase 3 clinical …
WEBAug 19, 2020 — GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that patient dosing has begun in a phase III clinical programme investigating its 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and …
WEBGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate.
GSK announces positive pivotal phase III data for 5-in-1 …
WEBMar 14, 2023 — GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III trial (NCT04502693) evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years.
London Stock Exchange | London Stock Exchange
WEB2 days ago — London Stock Exchange | London Stock Exchange ... null
WEBNew Ready-to-Use Single Vial Presentation. Menveo is a MenACWY vaccine product approved to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. Menveo is now available in two presentations:
Skip to content